BMS-936558 (MDX-1106) – pro

BMS-936558 is an antibody against PD-1, a protein involved in repressing the immune system. It activates the immune system and enables it to fight tumors. A well established approved drug, Yervoy blocks CTLA-4, another inhibitory protein expressed on immune cells and Yervoy and BMS-936558 belong to the same class of drugs. Both generate an anti-cancer immune response.

This very promising agents is in several trials for various diagnoses. For example, for renal cancer there is the Phase II trial of BMS-936558 (MDX-1106) in Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Tx and CA209-009 biolarker trial. There are also combination studies with several drugs in various malignancies. It is an promising agent but still investigational.

M. Sznol, J. D. Powderly, D. C. Smith, et al, Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol 28:15s, 2010 (suppl; abstr 2506)

D. F. McDermott, C. G. Drake,  et al, A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignanciesJ Clin Oncol 29: 2011 (suppl 7; abstr 331)

 

Participate in our Forums

To ask questions or participate in a discussion, please visit our Forums. You must LOGIN to participate.

Help Us Help Others

You can become a Site Sponsor. Or you may wish to support our work with a Donation.

Focused Articles For You

Lay Portal

Professional